Anhui Huaren Health Pharmaceutical (301408.SZ) subsidiary has received the drug registration acceptance notice for ferrous succinate tablets.
Huaren Health (301408.SZ) announced that its wholly-owned subsidiary Anhui Zhengyao Pharmaceutical Technology Co., Ltd. has received the "Acceptance Notice" for the drug registration and market approval application of Ferrous Succinate Tablets issued by the National Medical Products Administration.
Anhui Huaren Health Pharmaceutical (301408.SZ) announced that its wholly-owned subsidiary, Anhui Zhengyao Pharmaceutical Technology Co., Ltd., has received the "Acceptance Notification" for the drug registration application for Ferrous Succinate Tablets issued by the National Medical Products Administration.
Ferrous Succinate Tablets are an anti-anemia medication primarily used to treat and prevent iron deficiency anemia. This product, when taken orally, can supplement iron and correct iron deficiency anemia, and is suitable for adults and children suffering from iron deficiency anemia due to chronic blood loss, insufficient iron intake, or absorption disorders. It is also appropriate for the prevention of iron deficiency anemia in adults, pregnant women, and children. Patients should use the therapeutic dosage according to the medication instruction manual after being diagnosed with iron deficiency anemia. For daily preventive iron supplementation, a preventive dosage should be used.
Related Articles
Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.
HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.
HK Stock Market Move | WESTCHINACEMENT (02233) rose more than 10% during the session, expecting a net profit of up to 412 million yuan in the first half of the year, with overseas earnings growing against the trend.
Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.
HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.
HK Stock Market Move | WESTCHINACEMENT (02233) rose more than 10% during the session, expecting a net profit of up to 412 million yuan in the first half of the year, with overseas earnings growing against the trend.
RECOMMEND
